Skip to content
  • Mediacenter
  • Literature Database
  • Investor News
  • Careers
  • Get in Contact
International (English)
Locale
CytoSorbents Europe GmbH
International (English)
Locale
Hotline
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • Careers
    • Get in Contact

Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation – Teil I

Praktische Aspekte und neue Erfahrungen im Bereich Rhabdomyolyse

Praktische Aspekte und neue Erfahrungen im Bereich Sepsis und systemische Hyperinflammation – Teil 2

Introduction

Praktische Aspekte und neue Erfahrungen im Bereich Leberversagen

Liver toxin removal AND impact on inflammation to enhance clinical effects

Improved outcome of patients undergoing heart transplant with CytoSorb

Clinical effects of intraoperative hemoadsorption in acute infective endocarditis – A case series

Intraoperative removal of Ticagrelor to reduce bleeding complications in emergency cardiac surgery… – Experiences from Hamburg

MOF in ECMO patients and the impact of CytoSorb therapy – 3 years’ experience

CytoSorbents Europe GmbH
Facebook-f Twitter Linkedin Youtube

CytoSorbents Europe GmbH
Müggelseedamm 131
12587 Berlin

support(at)cytosorbents.com

©2023 CYTOSORBENTS EUROPE GMBH | ALL RIGHTS RESERVED

*CytoSorb Therapy is the use of the CytoSorb adsorber in conditions where elevated levels of Cytokines and/or Bilirubin and/or Myoglobin exist. CytoSorb can also be used intraoperatively for the removal of Ticagrelor and/or Rivaroxaban during Cardiopulmonary-Bypass.

  • Privacy Information
  • Data Protection
  • Disclaimer
  • Imprint
CytoSorbents Europe GmbH
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • Careers
    • Get in Contact
APPLY TODAY
JOBS
International (English)
  • Privacy Policy
  • Data protection
  • Disclaimer
  • Imprint